Provided by Tiger Trade Technology Pte. Ltd.

Oculis

13.18
+0.09500.73%
Post-market: 13.250.0700+0.53%19:30 EDT
Volume:150.39K
Turnover:1.97M
Market Cap:813.63M
PE:-7.68
High:13.25
Open:13.10
Low:12.87
Close:13.09
52wk High:34.48
52wk Low:10.52
Shares:61.73M
Float Shares:53.44M
Volume Ratio:0.86
T/O Rate:0.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7151
EPS(LYR):-2.3888
ROE:-43.70%
ROA:-24.95%
PB:2.98
PE(LYR):-5.52

Loading ...

Oculis Holding Price Target Maintained With a $44.00/Share by HC Wainwright & Co.

Dow Jones
·
Apr 21

Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema

GlobeNewswire
·
Apr 20

Oculis Holding: Needham Conference Visibility Reinforces Buy Rating and Upside Potential

TIPRANKS
·
Apr 15

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

GlobeNewswire
·
Apr 09

Gf Securities Highlights Investment Opportunities in Optical Circuit Switching Deployment

Stock News
·
Apr 08

Oculis to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Apr 07

Key Market Influencers: Bullish and Bearish Updates for April 7, 2026

Deep News
·
Apr 07

Stock Market Navigation: Announcements and Trading Alerts for Shanghai and Shenzhen Exchanges on April 7, 2026

Deep News
·
Apr 07

Ceasefire Rumors Emerge as Analyst Conducts High-Risk Field Research in Strait of Hormuz

Deep News
·
Apr 06

Luster Lighttech Describes OCS Application Landscape as "North America Leads, China Follows"

Deep News
·
Apr 03

Wuxi Taclink Optoelectronics Clarifies OCS Product Not Included in Near-Term Financial Forecasts

Stock News
·
Apr 03

April's Top Stock Picks Revealed: These Two Companies Garner Multiple Brokerage Endorsements

Deep News
·
Apr 01

Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis

GlobeNewswire
·
Mar 31

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

GlobeNewswire
·
Mar 28

Press Release: UTStarcom Reports Unaudited Financial Results for Second Half and Full Year 2025

Dow Jones
·
Mar 24

Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

GlobeNewswire
·
Mar 24

Stifel Raises Coherent Price Target to $275: 6.4T CPO Technology Shines at OFC 2026

Deep News
·
Mar 19

Optical Fiber Communication Conference (2026 OFC): Telecom Event Transforms into AI Infrastructure Showcase

Deep News
·
Mar 18

Three new option listings on March 17th

TIPRANKS
·
Mar 17

Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting

GlobeNewswire
·
Mar 16